ALZAMEND NEURO, INC. Net Income (Loss) Available to Common Stockholders, Basic
ALZAMEND NEURO, INC. (ALZN) reported Net Income (Loss) Available to Common Stockholders, Basic of $3.00 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-09-10
- ALZAMEND NEURO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-07-31 was $3.00M.
- ALZAMEND NEURO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-04-30 was -$2.87M.
- ALZAMEND NEURO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-01-31 was -$2.20M.
- ALZAMEND NEURO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-10-31 was -$1.00M.
- ALZAMEND NEURO, INC. net income (loss) available to common stockholders, basic for fiscal 2026 was -$8.77M.
- ALZAMEND NEURO, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$5.11M.
- ALZAMEND NEURO, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$9.95M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-07-31 | $3.00M 10-Q · filed 2026-09-10 | $130.05K derived: sum of 2 quarters · filed 2026-09-10 | -$2.07M derived: sum of 3 quarters · filed 2026-09-10 | -$3.07M derived: sum of 4 quarters · filed 2026-09-10 |
| 2026-04-30 | -$2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | -$5.07M derived: sum of 2 quarters · filed 2026-07-22 | -$6.07M derived: sum of 3 quarters · filed 2026-07-22 | -$8.77M 10-K · filed 2026-07-22 |
| 2026-01-31 | -$2.20M 10-Q · filed 2026-03-11 | -$3.20M derived: sum of 2 quarters · filed 2026-03-11 | -$5.90M 10-Q · filed 2026-03-11 | -$7.54M derived: sum of 4 quarters · filed 2026-07-22 |
| 2025-10-31 | -$1.00M 10-Q · filed 2025-12-09 | -$3.70M 10-Q · filed 2025-12-09 | -$5.35M derived: sum of 3 quarters · filed 2026-07-22 | -$6.42M derived: sum of 4 quarters · filed 2026-07-22 |
| 2025-07-31 | -$2.70M derived: 10-K 12 month − 3 quarters · filed 2026-07-22 | -$4.34M derived: sum of 2 quarters · filed 2026-07-22 | -$5.42M derived: sum of 3 quarters · filed 2026-07-22 | -$6.83M derived: sum of 4 quarters · filed 2026-07-22 |
| 2025-04-30 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | -$2.72M derived: sum of 2 quarters · filed 2026-07-22 | -$4.13M derived: sum of 3 quarters · filed 2026-07-22 | -$5.11M 10-K · filed 2026-07-22 |
| 2025-01-31 | -$1.07M 10-Q · filed 2026-03-11 | -$2.49M derived: sum of 2 quarters · filed 2026-03-11 | -$3.46M 10-Q · filed 2026-03-11 | |
| 2024-10-31 | -$1.42M 10-Q · filed 2025-12-09 | -$2.39M 10-Q · filed 2025-12-09 | ||
| 2024-04-30 | -$9.95M 10-K · filed 2025-07-22 | |||
| 2023-10-31 | -$2.91M 10-Q · filed 2024-12-11 | -$6.43M 10-Q · filed 2024-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |